131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study - PubMed
8 hours ago
- #enzalutamide
- #prostate cancer
- #radioligand therapy
- Phase 2 ARROW study evaluated 131I-LNTH-1095 radioligand therapy plus enzalutamide vs. enzalutamide alone in PSMA-positive metastatic castration-resistant prostate cancer.
- Primary endpoint was PSA50 response, significantly higher in the combination group (62.9%) vs. enzalutamide alone (31.3%).
- Median rPFS was 14.0 months for combination therapy vs. 11.5 months for enzalutamide alone, though not statistically significant.
- Grade ≥3 adverse events were more frequent with combination therapy (65.8%) vs. enzalutamide alone (41.0%), including fatigue, nausea, thrombocytopenia, and decreased appetite.
- Two treatment-related deaths occurred in the combination group.
- The study was not powered to detect differences in rPFS and OS.